FMT
NBIX icon

First Mercantile Trust’s Neurocrine Biosciences NBIX Stock Holding History

First Mercantile Trust’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-561
Closed -$49K – 886
2019
Q1 		$49K Sell
561
-3,806
-87% -$318K 0.01% 779
2018
Q4 		$312K Sell
4,367
-2,224
-34% -$213K 0.08% 298
2018
Q3 		$810K Sell
6,591
-254
-4% -$28.8K 0.16% 146
2018
Q2 		$672K Buy
6,845
+1,334
+24% +$119K 0.13% 177
2018
Q1 		$457K Buy
5,511
+2,256
+69% +$191K 0.1% 267
2017
Q4 		$253K Buy
+3,255
New +$222K 0.05% 466
2017
Q2 		– Sell
-3,082
Closed -$133K – 846
2017
Q1 		$133K Buy
3,082
+560
+22% +$24K 0.02% 682
2016
Q4 		$98K Sell
2,522
-1,375
-35% -$62.2K 0.02% 751
2016
Q3 		$197K Buy
3,897
+1,897
+95% +$94.5K 0.03% 619
2016
Q2 		$91K Sell
2,000
-2,805
-58% -$129K 0.01% 757
2016
Q1 		$190K Sell
4,805
-7,115
-60% -$282K 0.02% 598
2015
Q4 		$674K Buy
11,920
+2,465
+26% +$125K 0.07% 338
2015
Q3 		$376K Buy
+9,455
New +$457K 0.04% 540
2015
Q1 		– Sell
-12,800
Closed -$286K – 1111
2014
Q4 		$286K Buy
+12,800
New +$243K 0.02% 626
2013
Q3 		– Sell
-12,480
Closed -$167K – 1189
2013
Q2 		$167K Buy
+12,480
New +$153K 0.01% 781

Other funds holding NBIX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Mercantile Trust's NBIX Position: Q2 2019 in Review

First Mercantile Trust sold out of Neurocrine Biosciences (NBIX) in Q2 2019, closing a stake of 561 shares — an estimated $49K sold.

First Mercantile Trust first reported a position in NBIX in Q2 2013 and held it in 15 quarters. The position peaked at $810K in Q3 2018. 302 funds tracked by Wall St. Rank hold NBIX as of Q2 2019.

  • First Mercantile Trust reported no remaining Neurocrine Biosciences position as of Q2 2019 after selling out during the quarter.
  • First Mercantile Trust sold 561 Neurocrine Biosciences shares in Q2 2019, an estimated $49K.
  • First Mercantile Trust first reported a position in Neurocrine Biosciences in Q2 2013 and held it in 15 quarters.
  • First Mercantile Trust's Neurocrine Biosciences position peaked at $810K in Q3 2018.
  • 302 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2019.

Based on First Mercantile Trust's 13F filing for Q2 2019, filed 12 Aug 2019.